This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VACC Vaccitech (VACC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock About Vaccitech Stock (NASDAQ:VACC) Get Vaccitech alerts:Sign Up Key Stats Today's Range$1.25▼$1.3550-Day Range$1.19▼$5.0052-Week Range$1.64▼$5.10Volume36,832 shsAverage Volume244,643 shsMarket Capitalization$49.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. Read More Receive VACC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VACC Stock News HeadlinesReal-World Data on the RSV Vaccine for Older AdultsNovember 12, 2024 | msn.comBarinthus Bio completes enrolment in hepatitis B and prostate cancer vaccine trialsOctober 2, 2024 | finance.yahoo.com$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet. | Weiss Ratings (Ad)Buy Rating Affirmed on Barinthus Biotherapeutics Amid Promising Clinical Trials and Therapeutic AdvancesOctober 1, 2024 | markets.businessinsider.comBarinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate CancerOctober 1, 2024 | markets.businessinsider.comStrong Buy Rating for Barinthus Biotherapeutics Amid Promising Trials in Celiac and Hepatitis B TherapiesSeptember 26, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Barinthus Biotherapeutics Amid Promising Clinical AdvancementsAugust 12, 2024 | markets.businessinsider.comBRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024August 9, 2024 | markets.businessinsider.comSee More Headlines VACC Stock Analysis - Frequently Asked Questions How were Vaccitech's earnings last quarter? Vaccitech plc (NASDAQ:VACC) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.25. The firm earned $0.02 million during the quarter, compared to analyst estimates of $1.65 million. Vaccitech had a negative net margin of 409.18% and a negative trailing twelve-month return on equity of 23.41%. When did Vaccitech IPO? Vaccitech (VACC) raised $110 million in an initial public offering on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. What other stocks do shareholders of Vaccitech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccitech investors own include Intel (INTC), Johnson & Johnson (JNJ), Snap (SNAP), TJX Companies (TJX), Walt Disney (DIS), NIO (NIO) and Okta (OKTA). Company Calendar Last Earnings11/12/2021Today10/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VACC CIK1828185 Webwww.vaccitech.co.uk Phone44-18-6581-8808FaxN/AEmployees33Year Founded2016Profitability EPS (Trailing Twelve Months)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.34 million Net Margins-409.18% Pretax Margin-442.00% Return on Equity-23.41% Return on Assets-20.85% Debt Debt-to-Equity RatioN/A Current Ratio15.26 Quick Ratio15.26 Sales & Book Value Annual Sales$13.42 million Price / Sales3.70 Cash Flow$0.07 per share Price / Cash Flow19.30 Book Value$6.52 per share Price / Book0.20Miscellaneous Outstanding Shares38,547,000Free Float36,234,000Market Cap$49.73 million OptionableNot Optionable Beta-0.40 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:VACC) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredBuffett’s Retirement PlayIn 2022, when Larry Benedict called the peak of the market, those who stayed in oil were slaughtered. Meanw...Brownstone Research | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
